The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:

Cardiovascular MR imaging includes the complete anatomical display of the heart with CINE imaging of all phases of the heartbeat. Ultrafast techniques make breath hold three-dimensional coverage of the heart in different cardiac axes feasible. Cardiac MRI provides reliable anatomical and functional assessment of the heart and evaluation of myocardial viability and coronary artery disease by a noninvasive diagnostic imaging technique.
Cardiovascular MRI offers potential advantages over radioisotopic techniques because it provides superior spatial resolution, does not use ionizing radiation, has no imaging orientations constraints and contrast resolution better than echocardiography. It also offers direct visualization and characterization of atherosclerotic plaques and diseased vessel walls and surrounding tissues in cardiovascular research.
MRI perfusion approaches measure the alteration of regional myocardial magnetic properties after the intravenous injection of contrast agents and assess the extent of injury after a myocardial infarction and the presence of myocardial viability with a technique based on late enhancement. Extracellular MRI contrast agents, like Gd-DTPA, accumulate only in irreversibly damaged myocardium after a time period of at least 10 minutes.
This type of patients may also have an implanted cardiac stent, bypass or a cardiac pacemaker and special caution should be observed on the MRI safety and the contraindications. While a number of coronary stents have been tested and reported to be MRI compatible, coronary stents must be assessed on an individual basis, with the medical team weighing the risks and benefits of the MRI procedure.

Cardiac MRI overview:

Cardiovascular MRI has become one of the most effective noninvasive imaging techniques for almost all groups of heart and vascular disease.

(Cr(III)-labeled RBC's) Chromium labeled red blood cells have paramagnetic properties and potential as an intravascular MRI contrast agent. The labeling with chromium decreases the relaxation times of packed red blood cells (RBCs). The use of RBCs in nuclear medicine suggests a low toxicity.

See also Contrast Agents, Intravascular Contrast Agents, Blood Pool Agents.

Short name: Code 7228, generic name: Ferumoxytol, central moiety: Fe
Code 7228 is the code name for a substance in the development pipeline (AMAG Pharmaceuticals, Inc.) for use as a contrast agent in magnetic resonance angiography (MRA). Ferumoxytol, as a true blood pool agent, resides in the vascular space for an extended period of time and does not leak out into adjacent tissues like currently used gadolinium-based contrast agents. The product is being evaluated in MRA applications for the detection of blood flow in the heart muscle, in exploratory studies for the diagnosis of vulnerable plaque and as a next generation lymph node agent.
Code 7228 is currently in approval phase for use as an iron replacement therapeutic in chronic kidney disease patients receiving erythropoetin.
It is presently contemplated that Ferumoxytol will compete with the contrast agents Vasovist™ from EPIX Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham.

Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.